Receiver operating characteristic curve to predict anti-VEGF resistance in retinal vein occlusions and efficacy of Ozurdex

European Journal of Ophthalmology

Volumn 26, Issue 2, 2015, Pages 168-173

  Wolfe, Jeremy D ^a,b   Shah, Ankoor R ^a,b   Yonekawa, Yoshihiro ^a,b   Faran, Abdulrahman Al ^a   Franklin, Michael S ^c   Abbey, Ashkan M ^a,b   Capone, Antonio ^a,b  

^a ASSOCIATED RETINAL CONSULTANTS   (United States)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dexamethasone implant; Macular edema; Receiver operating characteristic curve; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; MACULAR EDEMA; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG IMPLANT; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; RETINAL VEIN OCCLUSION; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DRUG IMPLANTS; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84958746076     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000686     Document Type: Article

References (25)

1. Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2009;1:CD007324
2. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-91.
3. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-82.
4. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013; 97:278-84.
5. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429-37.
6. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012;119:2587-91.
7. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.
8. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-33.
9. Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology. 2012;119:132-7.
10. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011; 118:2453-60.
11. Haller JA, Bandello F, Belfort R Jr, et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117: 1134-6.
12. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-28.
13. Ip MS, Scott IU, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-14.
14. Labriola LT, Sadda SR. Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. Semin Ophthalmol. 2011;26:387-91.
15. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina. 2013;33:1227-31.
16. Meyer LM, Schönfeld CL. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther. 2013; 29:560-5.
17. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013;27:816-22.
18. Malclès A, Janin-Manificat H, Yhuel Y, et al. [Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases.] J Fr Ophtalmol. 2013;36:362-7.
19. Sugar EA, Jabs DA, Altaweel MM, et al; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152:1044-52.
20. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388-91.
21. Hsieh FTB. Nonparametric and semiparametric estimation of the receiver operating characteristic curve. Ann Stat. 1996;24:24-40.
22. Fawcett T. An Introduction to ROC analysis. Pattern Recognit Lett. 2006;27:861-74.
23. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013;120:1057-63.
24. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol. 2010;4:809-16.
25. Niv Y, Sperber AD. Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol. 1995;90:1974-7.